Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
复制标题
DOI：
10.1007/s00216-019-01932-w
复制
发表时间：
2019-08-01
影响因子：
4.3
通讯作者：
Beijnen, Jos H.
中科院分区：
文献类型：
--
作者：
Martinez-Chavez, Alejandra;Rosing, Hilde;Beijnen, Jos H.
A novel method was developed and validated for the quantification of the three approved CDK4/6 inhibitors (abemaciclib, palbociclib, and ribociclib) in both human and mouse plasma and mouse tissue homogenates (liver, kidney, spleen, brain, and small intestine) using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). For all matrices, pretreatment was performed using 50 mu L of sample by protein precipitation with acetonitrile, followed by dilution of the supernatant. Chromatographic separation of the analytes was done on a C18 column using gradient elution. A full validation was performed for human plasma, while a partial validation was executed for mouse plasma and mouse tissue homogenates. The method was linear in the calibration range from 2 to 200ng/mL, with a correlation coefficient (r) >= 0.996 for each analyte. For both human and mouse plasma, the accuracy and precision were within +/- 15% and
